Lonza - Custom Pharmaceutical and Biotechnological Manufacturing SolutionsLonza established the concept of custom manufacturing more than 20 years ago, recognising the trend toward outsourcing in the pharmaceutical industry. Since then, Lonza has been helping large and emerging pharmaceutical and biotechnology companies to meet their outsourcing needs by offering exclusive manufacturing services for the production of fine chemicals, intermediates, active pharmaceutical ingredients, peptides, oligonucleotides, recombinant therapeutic proteins, and monoclonal antibodies. These products are manufactured using Lonza's core custom pharmaceutical and biotechnological manufacturing technologies – chemical synthesis, microbial fermentation, mammalian cell culture and tides – and state-of-the-art cGMP compliant facilities around the globe. ADVANCED CHEMICAL SYNTHESISChemical synthesis for manufacturing small molecules is one of our key competences. We offer our customers the exclusive synthesis of fine chemical intermediates and API’s in compliance with cGMP requirements for use in pharmaceutical products. Lonza also offers its customers the synthesis of non-cGMP chemicals (advanced), intermediates and building blocks for the agrochemicals, pharmaceuticals, nutraceuticals and animal healthcare markets. Lonza's state-of-the-art chemical technology toolbox is based on a broad range of expertise at each of its manufacturing sites in Europe, North America and Asia. By utilising synergies that exist between biotechnology and classical chemistry, Lonza provides alternative and innovative manufacturing pathways. Our production capacity ranges from gram to multi-ton quantities. MICROBIAL FERMENTATIONSince 1983, Lonza has offered custom microbial fermentation and biotransformation services to supply intermediates and biologically active products to the life-sciences industry. These 'large' and 'small' molecule products are typically used in pharmaceutical, nutraceutical and cosmeceutical products, as well as food and feed additives Our microbial fermentation business capitalises on its close interaction with Lonza's chemical operations for biotransformations, purification and processing fermentation products by chemical process technology. MAMMALIAN CELL CULTURESLonza is a leader in exclusive contract manufacturing of monoclonal antibodies and recombinant proteins from mammalian cell culture. We currently have three state-of-the-art cGMP multi-product facilities around the world that can provide both clinical and commercial supply of products, and are building Asia's most advanced mammalian cell culture manufacturing facility in Tuas Biomedical Park, Singapore. The cell culture capacity that Lonza has established, and continues to expand, offers customers a truly global manufacturing presence, through a wide breadth of services (from early development to in-market supply). ADVANCED MANUFACTURING TECHNOLOGIES AND SERVICESWe are hard at work developing the world's most advanced pharmaceutical and biotechnological manufacturing processes for both mammalian and microbial products. Lonza's approach is based on providing a complete yet flexible development and manufacturing package created through close interactive partnerships with our customers. Lonza is able to provide a full development package, taking a product from vector construction and cell line development to full-scale manufacturing, including a full range of analytical services and regulatory support for clinical trials and in-market supply. Our customers regularly ask us to perform individual work packages or the complete pharmaceutical or biotechnological development programme.
MANUFACTURE OF PEPTIDES AND OLIGONUCLEOTIDESPeptides manufactured by Lonza have been extremely popular and successful for applications in the pharmaceutical, nutraceutical and cosmeceutical markets. This is primarily because we manufacture peptide and oligonucleotide products on both a large and small scale, under full cGMP conditions. Lonza is a trusted manufacturer with all three manufacturing technologies (solid, liquid, and recombinant), for the development of this class of products, and covers the breadth of services required from clinical trials through launch and in-market supply. SOLUTIONS FOR IMMEDIATE AND LONG-TERM NEEDSWe welcome the opportunity to be challenged by your manufacturing requirements. Whether you have immediate or long-term needs, Lonza is ready to help find a custom pharmaceutical or biotechnological manufacturing solution for you.
Lonza
|
![]() Our most important asset is our highly qualified personnel and their extensive expertise in responsive, process-oriented project management. | ||
![]() We offer a full range of research and services, from cell line development and process optimisation, to regulatory assistance and technology transfer support. | |||
![]() Our state-of-the art cGMP facilities will help you maximise every opportunity to gain an advantage in your race to market. | |||
![]() Lonza has developed a highly efficient mammalian expression and vector amplification system that makes use of selection via glutamine metabolism and powerful viral promoters. [© Martin Oeggerli] | |||
![]() Lonza is building Asia's most advanced mammalian cell culture manufacturing facility, in Tuas Biomedical Park, Singapore. |
